Howard Florey’s team gives penicillin its first human trial at Oxford

Story: 1941 C.E.  |  Last updated: February 12, 1941

It began with a dying police officer and a drug that could barely be produced in useful quantities. In early 1941 C.E., a team of scientists at the University of Oxford did something no one had ever done before: they injected a human being with purified penicillin and watched to see what would happen. What happened next changed the course of medicine forever — and also revealed, with painful clarity, how far there still was to go.

Key findings

• Penicillin clinical trials: Howard Florey and his Oxford team administered the first human doses of purified penicillin in February 1941 C.E., treating Albert Alexander, an Oxford police constable suffering from a life-threatening bacterial infection.
• Drug purification methods: Before any human trial was possible, Florey’s multidisciplinary team spent years developing techniques to grow, extract, and concentrate the antibiotic compound from mold cultures — work that Alexander Fleming had abandoned roughly a decade earlier.
• Nobel Prize recognition: Florey shared the 1945 C.E. Nobel Prize in Physiology or Medicine with Ernst Chain and Alexander Fleming for the discovery of penicillin and its curative effect in infectious diseases.

From abandoned experiment to working drug

Alexander Fleming had discovered penicillin in 1928 C.E. — famously observing that a mold contaminating one of his petri dishes was killing off surrounding bacteria. But Fleming could not stabilize or concentrate the compound, and he largely moved on. The discovery sat dormant for over a decade.

Howard Florey changed that. An Australian pharmacologist and pathologist who had come to Oxford on a Rhodes Scholarship and later led the Sir William Dunn School of Pathology, Florey was not the romantic lone genius of popular science mythology. He was a builder of teams. By the late 1930s C.E., he had assembled a group of biochemists, bacteriologists, and clinicians capable of tackling problems that no single discipline could solve alone.

Ernst Chain, a Jewish biochemist who had fled Nazi Germany, was central to the effort. Together, Chain and Florey found ways to grow penicillin-producing mold at scale, extract the active compound, and purify it enough to test safely in animals. When those tests showed the drug could eliminate bacterial infections in mice without killing them, the path to a human trial opened.

The first patient — and what went wrong

Albert Alexander, a 43-year-old Oxford police constable, had developed a severe infection after a scratch from a rosebush. By early 1941 C.E., the infection had spread across his face, scalp, and lungs. He was, by all clinical measures, dying.

Florey’s team began administering penicillin intravenously on February 12, 1941 C.E. Within 24 hours, Alexander’s condition improved dramatically. His fever dropped. The abscesses began to recede. For five days, the results were remarkable.

Then the penicillin ran out.

Florey’s team had even resorted to collecting Alexander’s urine and re-extracting traces of penicillin from it — a measure that speaks both to their ingenuity and to the drug’s desperate scarcity. Without enough to complete the course of treatment, the infection returned. Alexander died in March 1941 C.E.

Later trials — in Britain, the United States, and North Africa — told a different story. Once production scaled up, the results were extraordinary. By the end of World War II, penicillin was saving thousands of Allied soldiers from what would previously have been fatal wound infections.

A global effort behind one breakthrough

The penicillin story is often told as a British or European achievement. But the scaling of production was largely an American one. After Florey traveled to the United States in 1941 C.E. to enlist industrial and government support, U.S. pharmaceutical companies and the U.S. Department of Agriculture’s Northern Regional Research Laboratory became central to mass manufacturing. A laboratory assistant in Peoria, Illinois, found a mold growing on a cantaloupe that produced far more penicillin than any Oxford strain. Her name was rarely recorded; her contribution was essential.

The Nobel Committee’s 1945 C.E. award recognized Fleming, Florey, and Chain — though many historians note that Chain and Florey’s work was arguably more consequential than Fleming’s original observation. The politics of scientific credit are complicated, and Florey himself was notably uncomfortable with the public attention Fleming received.

Lasting impact

Florey’s estimates suggest the clinical development of penicillin has saved more than 80 million lives. That figure, while difficult to verify precisely, gives some sense of scale. Before antibiotics, a scratch, a tooth extraction, or a minor surgery could kill. Bacterial pneumonia, scarlet fever, syphilis, and wound infections were leading causes of death worldwide.

Penicillin didn’t just save lives — it created an entirely new field. Antibiotic medicine became a foundation of modern healthcare, enabling surgeries, chemotherapy, and organ transplants that would be impossible without infection control. The methodology Florey pioneered — systematic animal testing, toxicity screening, and controlled clinical trials — became the template for pharmaceutical development globally.

Florey’s work also led directly to the discovery of cephalosporins, a second major family of antibiotics, and his team’s approach influenced generations of researchers across disciplines. The Sir William Dunn School of Pathology at Oxford remains one of the world’s leading biomedical research institutions.

Australian Prime Minister Robert Menzies once said that in terms of world well-being, Florey was the most important person ever born in Australia. Whether or not that ranking holds, the clinical trials he led in 1941 C.E. represent one of the most consequential experiments in the history of medicine.

Blindspots and limits

Albert Alexander died, and his death is a reminder that the path from discovery to treatment is rarely clean or linear. More significantly, the mass production of antibiotics has contributed to one of the most serious public health challenges of the 21st century: antimicrobial resistance. The overuse and misuse of penicillin and related drugs has driven the evolution of bacteria that no existing antibiotic can reliably kill — a crisis the World Health Organization now identifies as one of the greatest threats to global health. Florey himself reportedly warned about the dangers of under-dosing and resistance as early as his 1945 C.E. Nobel lecture. The tool he gave the world came with instructions humanity has not always followed.

Read more

For more on this story, see: Wikipedia — Howard Florey

For more from Good News for Humankind, see:

• Alzheimer’s risk cut in half by drug in landmark prevention trial
• U.K. cancer death rates down to their lowest level on record
• The Good News for Humankind archive on global health

About this article

• 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
• 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
• 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
• ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.